174 related articles for article (PubMed ID: 15033429)
1. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Shoham S; Mazeh H; Javitt DC; Heresco-Levy U
Brain Res; 2004 Apr; 1004(1-2):142-7. PubMed ID: 15033429
[TBL] [Abstract][Full Text] [Related]
2. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
3. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
4. The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
Andreassen OA; Jørgensen HA
Life Sci; 1995; 57(24):2263-72. PubMed ID: 7475980
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum.
Roberts RC; Gaither LA; Gao XM; Kashyap SM; Tamminga CA
Synapse; 1995 Jul; 20(3):234-43. PubMed ID: 7570355
[TBL] [Abstract][Full Text] [Related]
7. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
Ikram H; Samad N; Haleem DJ
Pak J Pharm Sci; 2007 Jul; 20(3):188-95. PubMed ID: 17545102
[TBL] [Abstract][Full Text] [Related]
9. Effects of diphenyl-diselenide on orofacial dyskinesia model in rats.
Burger ME; Fachinetto R; Wagner C; Perottoni J; Pereira RP; Zeni G; Rocha JB
Brain Res Bull; 2006 Jun; 70(2):165-70. PubMed ID: 16782505
[TBL] [Abstract][Full Text] [Related]
10. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum.
Kelley JJ; Gao XM; Tamminga CA; Roberts RC
Exp Neurol; 1997 Aug; 146(2):471-8. PubMed ID: 9270058
[TBL] [Abstract][Full Text] [Related]
11. Effects of baclofen on reserpine-induced vacuous chewing movements in mice.
Castro JP; Frussa-Filho R; Fukushiro DF; Silva RH; Medrano WA; Ribeiro Rde A; Abílio VC
Brain Res Bull; 2006 Feb; 68(6):436-41. PubMed ID: 16459199
[TBL] [Abstract][Full Text] [Related]
12. Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system.
Sekiguchi K; Kanno H; Yamaguchi T; Ikarashi Y; Kase Y
Brain Res Bull; 2012 Dec; 89(5-6):151-8. PubMed ID: 22982367
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
14. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
[TBL] [Abstract][Full Text] [Related]
15. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
16. Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
[TBL] [Abstract][Full Text] [Related]
17. Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia.
Samad N; Haleem MA; Haleem DJ
Pak J Pharm Sci; 2008 Jul; 21(3):262-8. PubMed ID: 18614422
[TBL] [Abstract][Full Text] [Related]
18. Novel oral drug administration in an animal model of neuroleptic therapy.
Schleimer SB; Johnston GA; Henderson JM
J Neurosci Methods; 2005 Aug; 146(2):159-64. PubMed ID: 16054505
[TBL] [Abstract][Full Text] [Related]
19. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Burger ME; Fachineto R; Alves A; Callegari L; Rocha JB
Brain Res; 2005 Jan; 1031(2):202-10. PubMed ID: 15649445
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.
Andreassen OA; Aamo TO; Jøorgensen HA
Br J Pharmacol; 1996 Oct; 119(4):751-7. PubMed ID: 8904651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
